BIOHEART-B (02185) released its interim results, reporting a pre-tax loss of 33.375 million yuan, an increase of 21.72% year-on-year.
Baixin An-B (02185) announced its interim results for the six months ending June 30, 2026, reporting revenue of 14.377 million yuan, a decrease of 31.09% year-on-year; a pre-tax loss of 33.375 million yuan, an increase of 21.72% year-on-year; and a loss per share of 0.13 yuan.
BIOHEART-B (02185) announced its interim results for the six months ended June 30, 2026, reporting revenue of 14.377 million yuan, a year-on-year decrease of 31.09%; a pre-tax loss of 33.375 million yuan, an increase of 21.72% year-on-year; and a loss per share of 0.13 yuan.
For the six months ended June 30, 2026, the company recognized revenue of 14.4 million yuan (for the six months ended June 30, 2025: 20.9 million yuan), which includes sales of goods totaling 12.5 million yuan and 1.9 million yuan from collaborative income.
Related Articles
UBOT HOLDING (08529) released its interim results, reporting a profit attributable to shareholders of HKD 11.48 million, an increase of 117.84% compared to the previous year.
SKY BLUE 11(01010): Kong Wei Ci has been appointed as an independent non-executive director.
LANCANG TEA (06911) announced its interim results, with a profit attributable to owners of 2.415 million yuan, reversing the loss compared to the same period last year.
UBOT HOLDING (08529) released its interim results, reporting a profit attributable to shareholders of HKD 11.48 million, an increase of 117.84% compared to the previous year.
SKY BLUE 11(01010): Kong Wei Ci has been appointed as an independent non-executive director.
LANCANG TEA (06911) announced its interim results, with a profit attributable to owners of 2.415 million yuan, reversing the loss compared to the same period last year.
RECOMMEND
